The future of brain tumor treatment: integrating platelet-based liquid biopsy, advanced drug delivery systems, and eicosanoid inhibition
- 1Systems Pharmacology and Translational Therapeutics Laboratory, at the Center for Advanced Studies and Technology (CAST), and Department of Neuroscience, Imaging and Clinical Science, “G. d'Annunzio” University , ,
- 2Department of Biology and Biotechnology, University of Pavia , ,
Abstract
Despite extensive research, brain tumors still have some of the lowest survival rates among cancers. Their marked resistance to both conventional and emerging therapies stems from the unique properties of neural cells and their microenvironment, including the blood-brain barrier, cellular heterogeneity, and an immunosuppressive milieu. Addressing these challenges is essential for developing effective therapeutic strategies that improve patient outcomes. Advancements in brain tumor treatment depend on understanding the biological mechanisms behind potential drug targets and developing appropriate drug discovery strategies to inhibit them effectively. A major barrier remains the difficulty many drugs face in crossing the blood-brain barrier, which greatly restrains treatment effectiveness in brain tumor patients. Therefore, developing innovative drug delivery systems is essential. The brain exhibits a high concentration of fatty acids, notably polyunsaturated fatty acids such as arachidonic acid (AA), which are primarily esterified within membrane phospholipids. Upon release, cyclooxygenases, lipoxygenases, and cytochrome P450 enzymes can transform AA into various eicosanoid classes, producing lipid mediators involved in signal transduction pathways that regulate neurotransmission, neuroinflammation, and neuroplasticity. The diverse eicosanoid families can be synthesized within brain tumors and may contribute to tumor heterogeneity. This includes cell-specific eicosanoid production involving cancer cells, microglia, infiltrating immune cells, and platelets, each expressing distinct enzymes that facilitate tumor progression and immune evasion. This review examines the various mechanisms underlying brain cancer biology, with a particular focus on the roles of eicosanoids and their signaling pathways and how they affect tumor development, progression, and resistance to therapies. The review also describes therapeutic strategies targeting these pathways. The challenge of reduced responsiveness to therapeutic interventions is addressed through platelet-based drug delivery systems, which can increase efficacy by transporting chemotherapeutic agents directly to cancer cells. These systems also include nanoparticles coated with platelet membranes to evade immune clearance of intact cells and extracellular vesicles that provide high biocompatibility. Finally, tumor-educated platelets—which carry RNA and protein cargo—are presented as noninvasive biomarkers for diagnosing and monitoring disease progression and response to therapies in brain tumors.
Related
- Dual inhibition of p38α MAPK and Casein kinase δ/ϵ as a novel treatment strategy for AR-independent and taxane-resistant advanced prostate cancer
- Management of Advanced Tricompartmental Knee Osteoarthritis With Degenerative Meniscal Pathology Using Extracorporeal Magnetotransduction Therapy, Extracorporeal Shockwave Therapy, Microfragmented Adipose Tissue, and Platelet-Rich Plasma
- Comparison of bone repair of advanced platelet-rich fibrin (A-PRF) and leukocyte- and platelet-rich fibrin (L-PRF) following the extraction of impacted third molars: a randomized clinical trial.
- Integrating overall survival and health-related quality of life to prioritize first-line systemic therapies for unresectable advanced gastric cancer: a network meta-analysis
- Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
BibTeX
@article{berardino2026future,
title = {{The future of brain tumor treatment: integrating platelet-based liquid biopsy, advanced drug delivery systems, and eicosanoid inhibition}},
author = {Sara Di Berardino and Marta Zarà and Huzaifa Ali Ahfaz and Stefania Tacconelli and Paola Patrignani},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1956969},
url = {https://europepmc.org/article/PMC/PMC13668868},
note = {CC BY},
}
RIS
TY - JOUR
TI - The future of brain tumor treatment: integrating platelet-based liquid biopsy, advanced drug delivery systems, and eicosanoid inhibition
AU - Sara Di Berardino
AU - Marta Zarà
AU - Huzaifa Ali Ahfaz
AU - Stefania Tacconelli
AU - Paola Patrignani
PY - 2026
DA - 2026/10/01
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1956969
UR - https://europepmc.org/article/PMC/PMC13668868
AB - Despite extensive research, brain tumors still have some of the lowest survival rates among cancers. Their marked resistance to both conventional and emerging therapies stems from the unique properties of neural cells and their microenvironment, including the blood-brain barrier, cellular heterogeneity, and an immunosuppressive milieu. Addressing these challenges is essential for developing effective therapeutic strategies that improve patient outcomes. Advancements in brain tumor treatment depend on understanding the biological mechanisms behind potential drug targets and developing appropriate drug discovery strategies to inhibit them effectively. A major barrier remains the difficulty many drugs face in crossing the blood-brain barrier, which greatly restrains treatment effectiveness in brain tumor patients. Therefore, developing innovative drug delivery systems is essential. The brain exhibits a high concentration of fatty acids, notably polyunsaturated fatty acids such as arachidonic acid (AA), which are primarily esterified within membrane phospholipids. Upon release, cyclooxygenases, lipoxygenases, and cytochrome P450 enzymes can transform AA into various eicosanoid classes, producing lipid mediators involved in signal transduction pathways that regulate neurotransmission, neuroinflammation, and neuroplasticity. The diverse eicosanoid families can be synthesized within brain tumors and may contribute to tumor heterogeneity. This includes cell-specific eicosanoid production involving cancer cells, microglia, infiltrating immune cells, and platelets, each expressing distinct enzymes that facilitate tumor progression and immune evasion. This review examines the various mechanisms underlying brain cancer biology, with a particular focus on the roles of eicosanoids and their signaling pathways and how they affect tumor development, progression, and resistance to therapies. The review also describes therapeutic strategies targeting these pathways. The challenge of reduced responsiveness to therapeutic interventions is addressed through platelet-based drug delivery systems, which can increase efficacy by transporting chemotherapeutic agents directly to cancer cells. These systems also include nanoparticles coated with platelet membranes to evade immune clearance of intact cells and extracellular vesicles that provide high biocompatibility. Finally, tumor-educated platelets—which carry RNA and protein cargo—are presented as noninvasive biomarkers for diagnosing and monitoring disease progression and response to therapies in brain tumors.
SN - 1663-9812
ER -